and the Bayer Cross was used as the trademark for all of the I.G.'s pharmaceutical products. In the early 1930s, the Wupperal-Elberfeld facility continued its successful research into drugs to ...
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.
Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...
In a bold move to restore $540 million in cost savings, Bayer CEO Bill Anderson cut out ... teams with a clearer focused on our customers and products,” Hayes shares. Anderson’s push for ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...
The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...
At the same time, the value of our pipeline is growing by accelerating breakthrough innovations," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback